Opus Genetics (IRD) Cash from Financing Activities (2011 - 2026)

Opus Genetics (IRD) has 14 years of Cash from Financing Activities data on file, last reported at $27.6 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 34.84% year-over-year to $27.6 million in Q1 2026; TTM through Mar 2026 was $57.2 million, a 156.58% increase from a year earlier, with the FY2025 full-year figure at $50.0 million, up 1095.01% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $27.6 million, up from $24.1 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for IRD reached as high as $27.6 million in Q1 2026 and fell as low as -$83000.0 in Q4 2024.
• Historically, Cash from Financing Activities has averaged $6.3 million across 5 years, with a median of $1.6 million in 2022.
• Across the five-year window, Cash from Financing Activities soared 30125.0% in 2023 and slumped 102.3% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at -$12000.0 in 2022, then surged by 30125.0% to $3.6 million in 2023, then tumbled by 102.3% to -$83000.0 in 2024, then surged by 29146.99% to $24.1 million in 2025, then increased by 14.46% to $27.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $27.6 million in Q1 2026, $24.1 million in Q4 2025, and $4.5 million in Q3 2025.